NCT04412018View on ClinicalTrials.gov

An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 4, 2020

Primary Completion Date

November 6, 2020

Study Completion Date

December 12, 2020

Conditions
COVID-19Inflammatory Response
Interventions
DRUG

Icosapent ethyl

Icosapent ethyl (4 g BID for 3 days, then 2 g BID for the subsequent 11 days)

Trial Locations (1)

M6B 3H7

North York Diagnostic and Cardiology Clinic, Toronto

Sponsors
All Listed Sponsors
collaborator

Amarin Corporation

UNKNOWN

collaborator

HLS Therapeutics, Inc

UNKNOWN

lead

Canadian Medical and Surgical Knowledge Translation Research Group

OTHER